Türkiye-based veterinary vaccine manufacturer Dollvet Biyoteknoloji A.Ş. has reportedly entered the AgResults Foot-and-Mouth Disease (FMD) Vaccine Challenge Project, a US$17.34 million pay-for-results initiative managed by GALVmed. The programme is designed to accelerate the development, registration and commercial uptake of high-quality FMD vaccines tailored to the epidemiological needs of Eastern Africa.
Dollvet Biyoteknoloji A.Ş., a Turkish veterinary biologicals manufacturer, has been reported as a new competitor in the AgResults Foot-and-Mouth Disease Vaccine Challenge Project managed by GALVmed.
The reported participation places another vaccine manufacturer in an international initiative intended to address persistent limitations in FMD vaccine quality, affordability, regional suitability and access across endemic livestock markets.
The AgResults challenge was launched in February 2020 as an eight-year, US$17.34 million programme. It uses a results-based incentive structure to encourage manufacturers to develop and deliver vaccines that meet defined technical and market requirements.
For Dollvet, participation would provide an opportunity to demonstrate its vaccine-development capabilities in a programme focused on one of the most economically important transboundary livestock diseases.
Why the AgResults FMD Vaccine Challenge matters
Foot-and-mouth disease is a highly contagious viral disease affecting cloven-hoofed animals, including cattle, buffaloes, sheep, goats and pigs.
The disease can spread rapidly through susceptible populations and create significant economic losses through reduced milk production, lower weight gain, reproductive disruption, mortality in young animals and restrictions on livestock trade. Although vaccination is a central component of FMD control in endemic regions, vaccine effectiveness depends on several factors:
-
Antigenic match between vaccine strains and circulating field viruses.
-
Adequate antigen payload and vaccine potency.
-
Appropriate adjuvant formulation.
-
Duration and consistency of protective immunity.
-
Correct storage and administration.
-
Affordability and reliable availability.
These challenges are particularly important in Eastern Africa, where multiple FMD virus serotypes and topotypes circulate and livestock production systems include extensive smallholder and pastoral populations.
A vaccine that performs well in one epidemiological setting may not provide equivalent protection against a different circulating virus strain.
A US$17.34 million pay-for-results programme
The AgResults FMD Vaccine Challenge Project is structured as an eight-year, US$17.34 million competition. GALVmed serves as project manager, coordinating the programme’s technical and implementation activities.
The challenge combines vaccine development incentives with a distribution cost-share mechanism. The development phase encourages manufacturers to develop regionally relevant, high-quality vaccines that meet predefined Target Product Profile requirements.
The distribution cost-share phase, launched in October 2024, is designed to reduce the cost per dose for buyers and encourage wider adoption of qualifying products.
This is an important distinction from conventional grant-funded research. The programme is designed to reward defined outcomes and support market uptake rather than simply finance research activities.
The intended result is a more sustainable supply of vaccines that meet the requirements of endemic livestock markets.
Why regional vaccine suitability is critical
FMD is caused by a virus belonging to the genus Aphthovirus. Seven immunologically distinct serotypes are recognised: O, A, C, Asia 1, SAT 1, SAT 2 and SAT 3. Protection against one serotype does not necessarily provide protection against another. Even within a serotype, antigenic variation can affect the level of protection offered by a vaccine.
Eastern African countries face a particularly complex epidemiological environment, with SAT serotypes and other regionally important strains requiring careful vaccine selection. A quadrivalent vaccine approach can provide protection against multiple targeted serotypes, provided the selected antigens are appropriately matched and the product meets the required potency and quality specifications.
The AgResults programme has therefore placed emphasis on vaccines tailored to regional epidemiology rather than relying on a generic formulation.
Thermostability and potency: two important development priorities
The reported Dollvet participation is particularly relevant to the programme’s objective of supporting high-potency and thermostable vaccine solutions.
Vaccine potency – FMD vaccine potency is closely linked to the quantity and quality of antigen in the formulation and the immune response generated in vaccinated animals.
A high-potency product can be important in emergency vaccination campaigns and in areas where disease pressure is high.
However, potency must be demonstrated through validated testing and relevant challenge or protection data. It should not be inferred solely from antigen concentration or a manufacturer’s product description.
Thermostability – Maintaining vaccine quality in hot climates and remote livestock-production areas is a major logistical challenge.
Conventional cold-chain requirements can increase costs and create difficulties in delivering vaccines to pastoral and smallholder communities.
Improved thermostability could potentially reduce distribution constraints, but it must be established through validated stability studies. It does not mean that a vaccine can be stored or transported without temperature controls.
Dollvet’s potential role in the competitive landscape
The participation of another manufacturer could broaden the range of technologies and formulations evaluated through the challenge. For a manufacturer such as Dollvet, the programme could provide an opportunity to demonstrate:
-
FMD antigen-production capability.
-
Vaccine formulation and adjuvant technology.
-
Multi-serotype vaccine development.
-
Potency and safety testing.
-
Stability and shelf-life performance.
-
Manufacturing scalability.
-
Regulatory and market-access readiness.
The competitive process is also relevant to the wider veterinary vaccine manufacturing industry because it places technical performance and market delivery at the centre of product development.
The programme’s previously announced competitor participation by Boehringer Ingelheim in 2026 illustrates the involvement of established international vaccine manufacturers.
Formal qualification, product registration, approval by the programme’s judging process and commercial distribution remain distinct milestones.
Implications for East African livestock systems
A successful programme could have significant implications for cattle and small-ruminant production in endemic countries. Improved access to suitable vaccines could help national veterinary services and private-sector providers strengthen preventive vaccination programmes.
Potential benefits include:
-
Reduced FMD outbreaks and associated production losses.
-
Improved dairy and beef productivity.
-
Better protection of breeding animals.
-
Lower costs associated with emergency disease control.
-
Improved livestock-market confidence.
-
Greater resilience of smallholder and pastoral farming systems.
However, vaccine availability alone will not eliminate FMD. Effective control also requires surveillance, movement management, outbreak reporting, biosecurity, diagnostic capacity and coordinated vaccination strategies.
Strategic implications for the global veterinary vaccine industry
The challenge reflects a growing recognition that vaccine innovation must address the economics of delivery as well as biological performance. For vaccine manufacturers, the most important commercial questions include:
-
Can the product achieve the required protection against regionally relevant strains?
-
Can it be manufactured consistently at commercial scale?
-
Can the cost per dose be made affordable for national vaccination programmes?
-
Can distribution be sustained in remote areas?
-
Can the product meet the relevant regulatory requirements?
-
Can manufacturers support post-registration supply and quality assurance?
For African livestock markets, these factors are central to whether a vaccine becomes a commercially viable disease-control tool.
What to watch next
The key developments to monitor are confirmation of Dollvet’s formal competitor status, the specific product or vaccine formulation submitted, the applicable Target Product Profile requirements, any judging-panel decisions and subsequent registration or distribution milestones.
If confirmed and successfully advanced through the challenge, Dollvet’s participation would add another manufacturer to an international effort to improve FMD vaccine availability in endemic markets. The broader significance lies in the programme’s attempt to connect vaccine innovation with affordability, regional relevance and measurable field impact.
